X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform.
Lead Product(s): iPSC-derived Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Century Therapeutics
Deal Size: $45.0 million Upfront Cash: $45.0 million
Deal Type: Acquisition April 11, 2024
Details:
The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.
Lead Product(s): TEG002
Therapeutic Area: Oncology Product Name: GDT002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Gadeta
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2023
Details:
Proceeds from this financing will support the development of the Company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells.
Lead Product(s): Induced Pluripotent Stem Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona Ltd.
Deal Size: $87.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
